Telomir Pharmaceuticals Inc
telomirpharma.comWhat Do They Do?
Develops small-molecule drug candidates for age-related diseases and cancer, led by an investigational compound designed to alter metal balance inside cells.
10-K for FY2025, filed Mar 17, 2026Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics…View ↗
Telomir’s lead investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate…View ↗
We are a preclinical-stage pharmaceutical company focused on the development of novel small-molecule therapeutics targeting age-related…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 17, 2026
How Are They Changing?
-
Jun 8, 2026
CFO Alan Weichselbaum departed; Andriy Mushak was appointed
Mushak took the role of fractional CFO.
Sources
8-K, filed Jun 8, 2026
Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Telomir Pharmaceuticals, Inc. (the…View ↗
-
Apr 24, 2026
Acquired TELI and consolidated global rights to Telomir-1
The acquisition brought the worldwide Telomir-1 rights under one company.
Sources
8-K, filed Apr 24, 2026
The Transaction establishes Telomir as the sole holder of the global rights of Telomir-1 (Telomir-Zn), consolidating worldwide rights under…View ↗
Loading...
